180 reports of this reaction
1.7% of all DEFLAZACORT reports
#14 most reported adverse reaction
NASOPHARYNGITIS is the #14 most commonly reported adverse reaction for DEFLAZACORT, manufactured by PTC Therapeutics, Inc.. There are 180 FDA adverse event reports linking DEFLAZACORT to NASOPHARYNGITIS. This represents approximately 1.7% of all 10,344 adverse event reports for this drug.
Patients taking DEFLAZACORT who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASOPHARYNGITIS is a less commonly reported adverse event for DEFLAZACORT, but still significant enough to appear in the safety profile.
In addition to nasopharyngitis, the following adverse reactions have been reported for DEFLAZACORT:
The following drugs have also been linked to nasopharyngitis in FDA adverse event reports:
NASOPHARYNGITIS has been reported as an adverse event in 180 FDA reports for DEFLAZACORT. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASOPHARYNGITIS accounts for approximately 1.7% of all adverse event reports for DEFLAZACORT, making it a notable side effect.
If you experience nasopharyngitis while taking DEFLAZACORT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.